CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
February 11, 2025 16:01 ET
|
CRISPR Therapeutics AG
-2025 is poised to be a catalyst-rich year with key updates across several programs- -Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to...
CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
January 29, 2025 08:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones
January 13, 2025 07:00 ET
|
CRISPR Therapeutics AG
-Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across several programs- -Starting 2025 with a strong balance sheet with...
CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 08, 2025 08:30 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
January 07, 2025 08:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting
December 09, 2024 12:00 ET
|
CRISPR Therapeutics AG
-Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol- -Company announced...
CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference
November 14, 2024 08:30 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
November 07, 2024 08:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
November 05, 2024 09:01 ET
|
CRISPR Therapeutics AG
-CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized...
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
August 05, 2024 16:01 ET
|
CRISPR Therapeutics AG
-More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY™ and approximately 20 patients have had cells collected across all regions as of mid-July- -Clinical trials...